Table 1 Study participants’ demographic and health characteristics, stratified by tier 1 condition (n = 351a).
From: Clinical outcomes of a genomic screening program for actionable genetic conditions
Characteristic | FH (n = 93) | HBOC (n = 202) | Lynch (n = 56) | All study participants (n = 351a) | MyCode participants (n = 202,024) | P valuec | Active Geisinger patientsd (n = 917,910) | P valuec |
|---|---|---|---|---|---|---|---|---|
Female sex | 56 (60.2%) | 103 (51.0%) | 32 (57.1%) | 191 (54.4%) | 123,244 (61.0%) | 0.041 | 507,599 (55.3%) | 0.94 |
Race | 0.005 | <0.001 | ||||||
White | 92 (98.9%) | 201 (99.5%) | 56 (100%) | 349 (99.4%) | 194,226 (96.1%) | 855,152 (93.2%) | ||
African American | 1 (1.1%) | 1 (0.5%) | – | 2 (0.6%) | 5009 (2.5%) | 38,705 (4.2%) | ||
Other | – | – | – | – | 2789 (1.4%) | 24,053 (2.6%) | ||
Ethnicity | 0.026 | <0.001 | ||||||
Non-Hispanic/Non-Latino | 92 (98.9%) | 199 (98.5%) | 56 (100%) | 348 (99.2%) | 196,922 (97.5%) | 880,702 (96.0%) | ||
Other/Hispanic/Latino | 1 (1.1%) | 3 (1.5%) | – | 3 (0.8%) | 5102 (2.5%) | 37,208 (4.0%) | ||
Current smoker | 13 (14.0%) | 43 (21.3%) | 11 (19.6%) | 67 (19.1%) | 37,920 (18.8%) | 0.87 | 177,877 (19.4%) | 0.89 |
Alive at initial data pull | 93 (100%) | 194 (96.0%) | 56 (100%) | 343 (97.7%) | N/A | – | N/A | – |
Median age in years (IQR) | 62.7 (51.2, 72.0) | 62.6 (50.6–72.1) | 62.8 (53.8–73.8) | 62.7 (51.0–72.2) | 55.0 (40.0, 67.0) | <0.001 | 51.0 (34.0, 66.0) | <0.001 |
Median Charlson comorbidity index (IQR) | 5 (1–7) | 4 (2– 6) | 4 (2–6.5) | 4 (2–6) | 2 (0, 4) | <0.001 | 1 (0, 3) | <0.001 |
Median follow-up in months (IQR, range)b | 14.4 (12.8–30.5, 7.4–43.3) | 24.2 (21.1–32.8, 0.6–43.3) | 14.7 (12.6–28.9, 8.0–36.3) | 21.8 (14.5–30.6, 0.6–43.3) | N/A | – | N/A | – |
Prior genetic diagnosis | 0/93 (0%) | 39/202 (19.3%) | 7/56 (12.5%) | 46/351 (13.1%) | Not assessed | – | Not assessed | – |
